A Randomized, Double Blinded, Placebo Controlled Study to evaluate the efficacy and safety of investigational product Femildo(TM) in management of sexual dysfunction in women

Sexual dysfunction is highly associated with a number of dissatisfying personal experiences and relationships. A recent national survey found all categories of sexual dysfunction in women to have strong positive associations with low feelings of physical and emotional satisfaction and low feelings of happiness. Further, sexual dysfunction in women occurs more frequently than in men and thus potentially has a more negative impact upon their quality of life. Hypoactive sexual desire disorder (HSDD), the most prevalent female sexual health problem, was considered the persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity with marked distress or interpersonal difficulty not otherwise accounted for by a general medical or psychiatric condition. An HSDD may be primary or secondary, lifelong or acquired, or generalized or situational.

Several validated instruments for diagnosing HSDD now exist. For example, questionnaires such as the Brief Profile of Female Sexual Function (B-PFSF©) have been validated in the clinical setting for the diagnosis of HSDD. Hand in hand with the use of such tools is the need to establish a detailed history, in order to identify comorbidities or external causes. As there is no drug approved by the FDA for the treatment of sexual dysfunction in women, women often turn to over-the-counter remedies that promise to improve sexual functioning. There are many such remedies on the market today, but few have clinical trials to support their claims. Fortunately, women with low drive levels can get treatment to overcome the problem.